在SHP2上的热点酸化点驱动着蛋白激活和药物耐药性
Prashath Karunaraj1,2,3, Remkes Scheele1, Malcolm L Wells4
1Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA.
Research square
|August 13, 2025
概括
通过SRC家族激酶在氨酸62 (pY62) 中酸化SHP2,通过激活MAPK信号,导致对SHP2抑制剂的抵抗. 这个pY62站点代表了一种新的癌症药物标,与野生型SHP2不同.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- SHP2酸酶对于受体氨酸激酶 (RTK) 驱动的RAS/MAPK信号传递至关重要.
- SHP2 抑制剂的临床疗效有限,耐药性机制尚不清楚.
研究的目的:
- 确定对SHP2抑制剂产生初级耐药性的机制.
- 调查SHP2酸化在癌症信号和耐药性的作用.
主要方法:
- 蛋白质组分析以确定SHP2酸化热点.
- 生物化学测试以确定激酶活性和蛋白质相互作用.
- 生物物理分析以描述SHP2的构成和激活.
主要成果:
- 在氨酸62 (pY62) 中的SHP2酸化是RTK驱动瘤的热点.
- SRC家族激酶在Y62中直接酸化SHP2,独立于直接RTK酸化.
- SHP2 Y62D突变模仿构成性激活,导致MAPK通路激活和对全性SHP2抑制剂的抵抗.
结论:
- SHP2 pY62酸化是一种对SHP2抑制剂的初级耐药性机制,拷贝突变激活.
- 向SHP2 pY62提供了与野生型SHP2抑制独立的独特治疗策略.
相关概念视频
The JAK-STAT Signaling Pathway
9.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.2K
PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K
Amplifying Signals via Enzymatic Cascade
8.7K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.7K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Interactions Between Signaling Pathways
6.4K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K


